Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer.

ABSTRACT:

Background

Alterations in claudin expression can impair tight junction function, influence signaling pathways, and act as a tumor-promoting event in some epithelial cancers. Recently, zolbetuximab, a highly potent and tumor cell-selective therapeutic antibody against claudin 18.2, has been developed and investigated in clinical trials.

Methods

We conducted a prospective study using claudin 18.2 immunohistochemistry in 430 consecutive patients with advanced gastrointestinal, genitourinary, or rare cancers between June 2012 and March 2016.

Results

Claudin 18.2 expression was evaluated in 96.3% of the patients (414/430) using immunohistochemistry. In total, 4.1% (17/414) of the patients were claudin 18.2-positive, including patients with pancreatic (16.7%, 1/6), gastric

SUBMITTER: Hong JY 

PROVIDER: S-EPMC8797704 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature